Skip to main content

Pendulum: The Pioneers of Live Akkermansia

Clinically-studied, keystone strains designed to transform health through the gut microbiome.*

2026 07 Pendulum Logo 2025
Loading navigation...

Reimagine the health of your patients by targeting the gut microbiome

Using cutting-edge technology and microbiome science, Pendulum was the first company in the US to market live Akkermansia muciniphila. Akkermansia supports the synthesis of health-promoting postbioitics and strengthens gut barrier integrity.*

Pendulum’s Akkermansia-containing formulations have been clinically studied and published in the British Medical Journal. Improving gut barrier function and maintaining healthy blood sugar levels with Pendulum’s strains is a foundational way to help your patients find optimal health by harnessing the power of the gut microbiome.*

Pendulum is now the #1 GI Doctor recommended Akkermansia brand product.**


Survey

Fullscript and Pendulum provider survey with Akkermansia 500 Pro

98%

Will continue to recommend Akkermansia 500 Pro^

94%

Would recommend Akkermansia 500 Pro to other health care providers^

Study

Glucose control clinical efficacy

Pendulum conducted a double-blind, placebo-controlled nutrition study that demonstrated:

  • Pendulum Glucose Control’s safety for its intended use
  • Glucose control has a significant statistical and clinical impact on A1c and post-meal blood sugar spikes
  • -0.6 A1c reduction
  • -32.5% post prandial glucose spike reduction

References

**Based on sales data, 2022-2025
^Based on a IQVIA survey of gastroenterologists, 2025
‡Based on ERr 731®